Zai Lab (ZLAB) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price targets for Zai Lab's stock. Their ZLAB share price forecasts range from $70.00 to $130.00. On average, they predict the company's stock price to reach $94.33 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.

Zai Lab's stock was trading at $30.70 on January 1st, 2023. Since then, ZLAB shares have increased by 16.3% and is now trading at $35.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ZLAB earnings forecast.

Zai Lab Limited (NASDAQ:ZLAB) issued its earnings results on Tuesday, May, 9th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.43. The business had revenue of $62.80 million for the quarter, compared to analyst estimates of $65.21 million. Zai Lab had a negative trailing twelve-month return on equity of 37.58% and a negative net margin of 177.42%.

ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Global X MSCI China Health Care ETF (CHIH), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Invesco Golden Dragon China ETF (PGJ) and KraneShares MSCI All China Health Care Index ETF (KURE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.48%), FMR LLC (3.14%), Price T Rowe Associates Inc. MD (2.46%), Segantii Capital Management Ltd (2.33%), Credit Suisse AG (2.25%) and Genesis Investment Management LLP (1.60%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends.

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZLAB stock can currently be purchased for approximately $35.70.

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.50 billion and generates $231.11 million in revenue each year. The company earns $-443,290,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

The company employs 2,036 workers across the globe.

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.